NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NASDAQ:NURO opened at $0.71 on Tuesday. The stock has a market cap of $6.10 million, a P/E ratio of -1.00 and a beta of 2.28. The stock has a 50 day simple moving average of $0.83 and a 200 day simple moving average of $1.11. The company has a current ratio of 18.42, a quick ratio of 17.11 and a debt-to-equity ratio of 0.01. NeuroMetrix has a 1-year low of $0.64 and a 1-year high of $3.50.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.19) earnings per share for the quarter. The company had revenue of $1.66 million during the quarter. NeuroMetrix had a negative net margin of 75.17% and a negative return on equity of 24.38%.

Hedge Funds Weigh In On NeuroMetrix

Hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp bought a new position in shares of NeuroMetrix in the 2nd quarter valued at $41,000. Virtu Financial LLC bought a new position in shares of NeuroMetrix in the 1st quarter valued at $78,000. Millennium Management LLC increased its stake in shares of NeuroMetrix by 102.3% in the 4th quarter. Millennium Management LLC now owns 20,530 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 10,384 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of NeuroMetrix by 44.3% in the 3rd quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock valued at $97,000 after purchasing an additional 10,652 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of NeuroMetrix by 30.7% in the 4th quarter. Renaissance Technologies LLC now owns 36,854 shares of the medical device company’s stock valued at $55,000 after purchasing an additional 8,654 shares during the last quarter. Institutional investors own 5.07% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.